Results IPSS mean change was-3.7±3.0 (95% CI-4.3 to-3.2) after 12 months of Afalaza (vs.-
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …

The progression of benign prostatic hyperplasia (BPH) can be defined as a deterioration of
clinical variables such as lower urinary tract symptoms (LUTS), health‐related quality of life …

BACKGROUND:: Trials of monotherapy with α1-adrenergic-receptor antagonists (α1ARAs)
and 5a-reductase inhibitors (5ARIs) have found that the former drug class is effective in …

OBJECTIVES To assess the 3‐year efficacy and safety of the selective α1‐blocker alfuzosin
at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign …

Objectives: To assess the additive benefit of combining an α 1-blocker and a 5α-reductase
inhibitor. Methods: This European, randomized, double-blind, multicenter trial involved …

OBJECTIVES: In real-life clinical practice, we determined the incidence of acute urinary
retention (AUR) and benign prostatic hyperplasia (BPH)-related surgery in patients with BPH …

In 1999, a meta-analysis on the efficacy and tol-erability of α1-adrenoceptor (α1-AR)
antagonists in treating lower urinary tract symptoms (LUTS) suggestive of benign prostatic …

Aims: The aim of this study was to assess patient outcome after discontinuation of alfuzosin
treatment in patients with benign prostatic hyperplasia (BPH). Methods: This study included …

Purpose We compared the effects of alpha-adrenergic receptor blocker (α-blocker)
monotherapy with those of combination therapy with α-blocker and 5-alpha-reductase …

The management of symptomatic benign prostatic hyperplasia (BPH) continues to evolve,
with new techniques and forms of medical management being introduced and traditional …